2023
Sex effects in predictors of smoking abstinence and neuropsychiatric adverse events in the EAGLES trial
McKee S, Lawrence D, Saccone P, McRae T, Anthenelli R. Sex effects in predictors of smoking abstinence and neuropsychiatric adverse events in the EAGLES trial. Drug And Alcohol Dependence Reports 2023, 8: 100177. PMID: 37520849, PMCID: PMC10372180, DOI: 10.1016/j.dadr.2023.100177.Peer-Reviewed Original ResearchNeuropsychiatric adverse eventsCessation outcomesContinuous abstinenceAdverse eventsPsychiatric cohortPsychiatric statusLower oddsEfficacy of vareniclineSmoking cessation medicationsPoint prevalence abstinenceHigher baseline levelsSex effectsLogistic regression modelsEAGLES trialCessation medicationsBaseline characteristicsSmoking historyMedication useNicotine patchPoint prevalenceStudy treatmentBaseline variablesBaseline cigarettesAbstinence outcomesSignificant interaction
2015
Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis
McKee SA, Smith PH, Kaufman M, Mazure CM, Weinberger AH. Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis. Nicotine & Tobacco Research 2015, 18: 1002-1011. PMID: 26446070, PMCID: PMC5942618, DOI: 10.1093/ntr/ntv207.Peer-Reviewed Original ResearchConceptsSmoking cessation medicationsCessation medicationsSmoking cessationDouble-blind placebo-controlled trialEfficacy of vareniclinePlacebo-controlled trialShort-term outcomesClinical trial dataSex differencesSimilar ratesWeek 52Week 24Women smokersNicotine replacementWeek 12Outcome endpointsTherapeutic responseClinical trialsContinuous abstinenceVarenicline's efficacyVareniclinePlacebo outcomesEqual efficacySex disparitiesEffective FDA